Home > Insider Trading > Filing (0000950170-24-027510)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1778307	Andrew Cheng	C/O Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-03-04	57,733	$16.00	649,149	No	4	M	Direct
Common Stock	Acquisiton	2024-03-04	17,267	$21.10	666,416	No	4	M	Direct
Common Stock	Disposition	2024-03-04	35,827	$31.40	630,589	No	4	S	Direct
Common Stock	Disposition	2024-03-04	6,770	$32.28	623,819	No	4	S	Direct
Common Stock	Disposition	2024-03-04	9,614	$33.83	614,205	No	4	S	Direct
Common Stock	Disposition	2024-03-04	14,680	$34.63	599,525	No	4	S	Direct
Common Stock	Disposition	2024-03-04	7,995	$35.49	591,530	No	4	S	Direct
Common Stock	Disposition	2024-03-04	114	$36.28	591,416	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-03-04	57,733	$0.00	57,733	$16.00
Common Stock	Stock Option (Right to Buy)	Disposition	2024-03-04	17,267	$0.00	17,267	$21.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
10,000		2029-06-18	No	4	M	Direct
244,395		2031-12-07	No	4	M	Direct

Footnotes

The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person
Includes 505 shares acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2023.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.11 to $32.09, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.12 to $32.85, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.19 to $34.18, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.19 to $35.18, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.245 to $36.16, inclusive.
The options are vested and currently exercisable.